A double-blind study was carried out to investigate the possibility of therapeutic effect of levamisole on recurrent progenital herpes. One hundred and nine patients, including 53 females, entered the study, but only 75 completed. Levamisole, 50 mg three times daily for 3 days, was started at the first sign of recurrence. The study period consisted of 6 visits or 12 months, whichever came first. No statistical differences were observed between levamisole and placebo groups when comparing the duration of the lesion and the degree of pain, although less pain was observed among those on levamisole. The interval between attacks was increasingly prolonged in the levamisole-treated group, and reached a significant level at the sixth visit. However, analysis on the basis of mean cumulative number of days between attacks showed no significant differences throughout the study period. Because of occasional neutropenia and generalized urticaria, and because of the absence of clear-cut clinical improvement of statistical significance, levamisole was considered of limited benefit to patients with recurrent genital herpes infection.
A double-blind study was carried out to investigate the possibility of therapeutic effect of levamisole on recurrent progenital herpes. One hundred and nine patients, including 53 females, entered the study, but only 75 completed. Levamisole, 50 mg three times daily for 3 days, was started at the first sign of recurrence. The study period consisted of 6 visits or 12 months, whichever came first. No statistical differences were observed between levamisole and placebo groups when comparing the duration of the lesion and the degree of pain, although less pain was observed among those on levamisole. The interval between attacks was increasingly prolonged in the levamisole-treated group, and reached a significant level at the sixth visit. However, analysis on the basis of mean cumulative number of days between attacks showed no significant differences throughout the study period. Because of occasional neutropenia and generalized urticaria, and because of the absence of clear-cut clinical improvement of statistical significance, levamisole was considered of limited benefit to patients with recurrent genital herpes infection.
Levamisole hydrochloride is a phenyl-thiazolidine with anthelmintic and antianergic properties. It may restore the function of phagocytes and T-lymphocytes in compromised hosts, but is without effect on cells from normal hosts. It does not seem to affect B-cells directly (1, 5, 9).
Recurrent herpes simplex infection involving the genital tract has become a common problem during recent years, especially among young adults. Since there is no cure for this condition, and since there is some evidence to indicate an association between the recurrence of herpes simplex and decreased cell-mediated immunity towards the herpes viral antigens (3, 6, 7) , attempts have been made to study the effects of levamisole on recurrent herpes infection. Earlier reports indicated that levamisole administration was beneficial to herpes labialis. The frequency, duration, and intensity of attacks decreased in a majority of patients. Genital herpes responded less well to levamisole than herpes labialis (2, 4, 8) . A double-blind study in Figure 1 shows the effect of levamisole on the duration of lesions. Starting from the pretreat-810 CHANG AND FIUMARA ment visit and through six visits or recurrences, the data did not reveal any statistical differences between levamisole and placebo groups.
The effect of levamisole on pain is shown in Fig. 2 . The numbers 1, 2, 3, and 4 represent the degree of pain: severe, moderate, slight, and none, respectively. There was a general tendency for pain to diminish following each attack, but the decrease ran parallel to both placebo and levamisole groups. Although less pain was seen with levamisole, the difference was not statistically significant.
The effect of levamisole on the frequency of recurrence is shown in Fig. 3 . None of the differ- ences between levamisole and placebo groups had reached a significant level with the exception of that observed during the last period (P = 0.05). However, further analysis based on the cumulative number of days between attacks failed to substantiate the significance (Fig. 4) .
Side effects included dysgeusia, or change of taste, and hyperosmia, or abnormal sense of smell, which were observed in about a third of patients on levamisole. Occasional nausea was reported. Two patients had transient neutropenia of mild degree. Two others developed generalized urticarial lesions with edema of both hands, which required prednisone treatment. 
